{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Raltegravir&page=5", "query": { "intervention": "Raltegravir", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 125, "total_pages": 13, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Raltegravir&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Raltegravir&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-17T14:42:33.460Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00843713", "title": "Effect of Raltegravir on Endothelial Function in HIV-Infected Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HIV Infection", "Inflammation", "Cardiovascular Disease", "HIV Infections" ], "interventions": [ { "name": "raltegravir", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 56, "start_date": "2009-01", "completion_date": "2014-02", "has_results": true, "last_update_posted_date": "2018-12-12", "last_synced_at": "2026-10-17T14:42:33.460Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00843713" }, { "nct_id": "NCT00782301", "title": "Maraviroc Versus Etravirine In Combination With Antiretroviral Therapy In Drug Experienced HIV And Hepatitis Co-Infected Patients", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Hepatitis B", "Human Immunodeficiency Virus", "Hepatitis C, Chronic" ], "interventions": [ { "name": "maraviroc", "type": "DRUG" }, { "name": "etravirine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 0, "start_date": "2009-03", "completion_date": "2010-02", "has_results": false, "last_update_posted_date": "2012-01-19", "last_synced_at": "2026-10-17T14:42:33.460Z", "location_count": 15, "location_summary": "Clearwater, Florida • Orlando, Florida • Safety Harbor, Florida + 10 more", "locations": [ { "city": "Clearwater", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Safety Harbor", "state": "Florida" }, { "city": "Wilton Manors", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00782301" }, { "nct_id": "NCT02605954", "title": "Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "E/C/F/TAF", "type": "DRUG" }, { "name": "ABC/3TC", "type": "DRUG" }, { "name": "Third Antiretroviral Agent", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 275, "start_date": "2015-11-18", "completion_date": "2018-01-24", "has_results": true, "last_update_posted_date": "2018-11-14", "last_synced_at": "2026-10-17T14:42:33.460Z", "location_count": 12, "location_summary": "Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 8 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Fort Lauderdale", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02605954" }, { "nct_id": "NCT02858401", "title": "Safety and Biological Activity of Vesatolimod in HIV-1 Infected, Virologically Suppressed Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "Vesatolimod", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "ARV regimen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2015-01-29", "completion_date": "2019-02-14", "has_results": true, "last_update_posted_date": "2020-02-21", "last_synced_at": "2026-10-17T14:42:33.460Z", "location_count": 8, "location_summary": "Los Angeles, California • San Diego, California • Ft. Pierce, Florida + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Ft. Pierce", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02858401" }, { "nct_id": "NCT04442737", "title": "A Study of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Evaluated as a Fixed Dose Combination Regimen in Participants Switching From an Integrase Inhibitor Who Have Experienced Rapid Weight Gain", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HIV-1" ], "interventions": [ { "name": "D/C/F/TAF FDC", "type": "DRUG" }, { "name": "TAF/FTC FDC", "type": "DRUG" }, { "name": "INI Based Regimen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Scientific Affairs, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 103, "start_date": "2020-07-01", "completion_date": "2023-08-30", "has_results": true, "last_update_posted_date": "2025-03-30", "last_synced_at": "2026-10-17T14:42:33.460Z", "location_count": 34, "location_summary": "Birmingham, Alabama • Bakersfield, California • Beverly Hills, California + 28 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Bakersfield", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Ft. Pierce", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04442737" }, { "nct_id": "NCT00976404", "title": "Therapeutic Intensification Plus Immunomodulation to Decrease the HIV-1 Viral Reservoir", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infection" ], "interventions": [ { "name": "DNA + HIV-rAd5 vaccine", "type": "BIOLOGICAL" }, { "name": "ART intensification (raltegravir)", "type": "DRUG" }, { "name": "ART intensification (maraviroc)", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Robert L. Murphy", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 28, "start_date": "2009-11", "completion_date": "2014-06", "has_results": true, "last_update_posted_date": "2014-09-12", "last_synced_at": "2026-10-17T14:42:33.460Z", "location_count": 3, "location_summary": "San Francisco, California • Chicago, Illinois • New York, New York", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00976404" }, { "nct_id": "NCT00749580", "title": "A Pilot,Raltegravir Versus NRTIs as a Backbone Switched From a Stable Boosted PI Regimen", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Virus Diseases", "HIV" ], "interventions": [ { "name": "Switch NRTIs as a Backbone to Raltegravir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of South Florida", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 46, "start_date": "2008-11", "completion_date": "2011-07", "has_results": true, "last_update_posted_date": "2014-12-17", "last_synced_at": "2026-10-17T14:42:33.460Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00749580" }, { "nct_id": "NCT00811954", "title": "Comparative Study of Three NNRTI-Sparing HAART Regimens", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infection" ], "interventions": [ { "name": "Emtricitabine/tenofovir disoproxil fumarate", "type": "DRUG" }, { "name": "Raltegravir", "type": "DRUG" }, { "name": "Darunavir", "type": "DRUG" }, { "name": "Ritonavir", "type": "DRUG" }, { "name": "Atazanavir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1814, "start_date": "2009-05", "completion_date": "2013-06", "has_results": true, "last_update_posted_date": "2014-09-05", "last_synced_at": "2026-10-17T14:42:33.460Z", "location_count": 55, "location_summary": "Birmingham, Alabama • Long Beach, California • Los Angeles, California + 39 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00811954" }, { "nct_id": "NCT00700115", "title": "Kaletra-isentress Treatment Evaluation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Kaletra + Isentress", "type": "DRUG" }, { "name": "Pre-study antiretroviral regimen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2008-06", "completion_date": "2011-01", "has_results": true, "last_update_posted_date": "2014-12-12", "last_synced_at": "2026-10-17T14:42:33.460Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00700115" }, { "nct_id": "NCT00738569", "title": "Assess the Downregulation of HIV-1 When Raltegravir is Added to a Virologically Suppressed HAART Regimen", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HIV" ], "interventions": [ { "name": "Raltegravir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Jewish Health", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2008-07", "completion_date": "2011-02", "has_results": false, "last_update_posted_date": "2021-01-19", "last_synced_at": "2026-10-17T14:42:33.460Z", "location_count": 1, "location_summary": "Denver, Colorado", "locations": [ { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00738569" } ] }